Online citations, reference lists, and bibliographies.
← Back to Search

Second-line Gemcitabine-based Chemotherapy Regimens Improve Overall 3-year Survival Rate In Patients With Malignant Pleural Mesothelioma: A Multicenter Retrospective Study

H. Mutlu, Ş. Gündüz, H. Karaca, Abdullah Büyükçelik, Yasemin Benderli Cihan, A. Erden, Zeki Akça, H. Çoşkun
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
In the present study, we aimed to evaluate the effectiveness of second-line gemcitabine-based chemotherapy regimens on overall survival (OS) in malignant pleural mesothelioma (MPM) patients receiving first-line pemetrexed-based regimens. A total of 73 patients with MPM from Akdeniz University, Acibadem Kayseri Hospital, Kayseri Training and Research Hospital, and Erciyes University were analyzed and evaluated retrospectively as two groups: second-line gemcitabine-based chemotherapy and no second-line chemotherapy. The median OS of patients who received second-line gemcitabine-based chemotherapy was 11.3 (5.1–17.5) months, while it was 9.9 (2.1–17.7) months in the patients who did not receive chemotherapy in the second-line setting (p = 0.056). When we evaluated the survival rate at the 6th, 12th, 18th, 24th, and 36th month, the OS rate of the 36th month was significantly higher in patients who received gemcitabine-based second-line chemotherapy (p = 0.041). When evaluating the OS from diagnosis to death, the median OS values were 20.8 (17.5–24.1) months for first-line pemetrexed-based regimens then second-line gemcitabine alone and 13.1 (9.0–17.1) months supportive care after first-line pemetrexed-based regimens (p = 0.005). According to our results, we may consider gemcitabine-based regimens as second-line chemotherapy after treatment with pemetrexed plus platinum in patients with MPM.
This paper references
10.1097/01.coc.0000144852.75613.56
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
10.1097/COC.0b013e3181cae90e
Phase II Study of Gemcitabine Plus Docetaxel as Second-Line Treatment in Malignant Pleural Mesothelioma: A Single Institution Study
Ioannis S Tourkantonis (2011)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Mesothelioma: a review.
F. Mott (2012)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1002/cncr.23337
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
Associazione Italiana pneumologi ospedalieri thoracic oncology study group. Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma
L Portalone (2005)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1016/J.PNEUMO.2010.07.013
Traitement de seconde ligne dans le mésothéliome pleural malin. Étude rétrospective française (2005–2006)
J. Margery (2010)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.LUNGCAN.2006.04.014
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
G. Utkan (2006)
10.7314/APJCP.2013.14.6.3887
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
H. Mutlu (2013)
10.1016/j.pneumo.2010.07.013
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
J. Margery (2010)
10.1007/978-1-4757-3656-4
AJCC Cancer Staging Manual
M. B. Amin (2002)
an observational study
A Xanthopoulos (2014)
1555–61
Ceresoli GL Garassino I De Vincenzo F Cavina R Campagnoli E Zucali PA (2014)
10.1007/s10147-013-0619-5
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy
G. Toyokawa (2013)
10.1177/030089160509100104
Epirubicin and Gemcitabine as First-Line Treatment in Malignant Pleural Mesothelioma
L. Portalone (2005)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1016/J.LUNGCAN.2007.09.018
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
10.1186/1745-6673-3-34
Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study
A. Xanthopoulos (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar